AU2023435819A1 - Drug combination for treatment of pancreatic cancer - Google Patents

Drug combination for treatment of pancreatic cancer

Info

Publication number
AU2023435819A1
AU2023435819A1 AU2023435819A AU2023435819A AU2023435819A1 AU 2023435819 A1 AU2023435819 A1 AU 2023435819A1 AU 2023435819 A AU2023435819 A AU 2023435819A AU 2023435819 A AU2023435819 A AU 2023435819A AU 2023435819 A1 AU2023435819 A1 AU 2023435819A1
Authority
AU
Australia
Prior art keywords
treatment
pancreatic cancer
drug combination
drug
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023435819A
Other languages
English (en)
Inventor
Ashok Kumar SALUJA
Mohana R. VELAGAPUDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minneamrita Therapeutics LLC
Original Assignee
Minneamrita Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minneamrita Therapeutics LLC filed Critical Minneamrita Therapeutics LLC
Publication of AU2023435819A1 publication Critical patent/AU2023435819A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023435819A 2023-03-09 2023-03-21 Drug combination for treatment of pancreatic cancer Pending AU2023435819A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363489221P 2023-03-09 2023-03-09
US63/489,221 2023-03-09
PCT/US2023/015813 WO2024186320A1 (en) 2023-03-09 2023-03-21 Drug combination for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
AU2023435819A1 true AU2023435819A1 (en) 2025-10-02

Family

ID=92675407

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023435819A Pending AU2023435819A1 (en) 2023-03-09 2023-03-21 Drug combination for treatment of pancreatic cancer

Country Status (5)

Country Link
EP (1) EP4676463A1 (cg-RX-API-DMAC7.html)
JP (1) JP2026507878A (cg-RX-API-DMAC7.html)
KR (1) KR20250154513A (cg-RX-API-DMAC7.html)
AU (1) AU2023435819A1 (cg-RX-API-DMAC7.html)
WO (1) WO2024186320A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596977B (zh) 2009-05-07 2016-06-29 明尼苏达大学评议会 雷公藤内酯前药
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
WO2015127011A1 (en) * 2014-02-21 2015-08-27 Institute Of Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center C-myc as a biomarker for tumor sensitivity to treatment with rna polymerase ii inhibition
US10975146B2 (en) * 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US11819498B2 (en) * 2019-12-30 2023-11-21 Unm Rainforest Innovations Methods and compositions for treating autophagy related disease states and conditions utilizing AMPK activation
WO2021231678A1 (en) * 2020-05-13 2021-11-18 University Of Massachusetts Reducing prominin2-mediated resistance to ferroptotic cell death

Also Published As

Publication number Publication date
JP2026507878A (ja) 2026-03-06
EP4676463A1 (en) 2026-01-14
WO2024186320A1 (en) 2024-09-12
KR20250154513A (ko) 2025-10-28

Similar Documents

Publication Publication Date Title
CA3261042A1 (en) KRAS MACROCYCLIC INHIBITORS FOR CANCER TREATMENT
EP4010081A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
EP4119156A4 (en) MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
EP4360649A4 (en) MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
EP4119157A4 (en) MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
EP3989985A4 (en) METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER
AU2021372815A9 (en) Combination treatment of cancer
EP4226945A4 (en) MEDICATION FOR THE TREATMENT OF CANCER
HK40116983A (en) Combination therapy for treatment of cancer
HK40120366A (zh) 癌症的治疗
HK40128038A (en) Combination therapies for treatment of cancer
CA3263276A1 (en) Polytherapy for the treatment of cancer
CA3273958A1 (en) Methods of treating pancreatic cancer
CA3302582A1 (en) Molecules for treatment of cancer
EP4363855A4 (en) DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER
HK40130970A (en) Combination therapy for the treatment of cancer
CA3271803A1 (en) Combination therapy for the treatment of cancer
HK40129364A (en) Combination therapy for the treatment of cancer
HK40114518A (en) Combination therapy for the treatment of cancer
CA3296090A1 (en) Psma-targeted radiopharmaceuticals for treatment of cancer
AU2024298849A1 (en) Psma-targeted radiopharmaceuticals for treatment of cancer
CA3277833A1 (en) Medicament for treatment and/or prevention of cancer
CA3264563A1 (en) Medicament for treatment and/or prevention of cancer
CA3264839A1 (en) Medicament for treatment and/or prevention of cancer
CA3265629A1 (en) Medicament for treatment and/or prevention of cancer